Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
What does it do?
Editas Medicine is a biotech company trying to fix diseases at the DNA level using a technology called CRISPR — think of it like a molecular cut-and-paste tool for your genes. Their biggest current project, EDIT-401, aims to lower 'bad' LDL cholesterol by editing the liver cells responsible for clearing it from your blood — a potential one-time treatment instead of daily pills. They're also working on sickle cell disease and beta thalassemia, which are inherited blood disorders that cause serious lifelong illness. The idea is that one injection could fix the root genetic cause permanently, rather than just managing symptoms.
CRISPR gene editing is one of the most watched areas in medicine right now — a rival company, Vertex and CRISPR Therapeutics, already got FDA approval for a CRISPR-based sickle cell cure in late 2023, proving the technology actually works in humans. That approval was a landmark moment that validated the entire field, and Editas is betting it can follow with its own therapies. With cardiovascular disease being the world's biggest killer, a one-time CRISPR fix for high cholesterol would be a blockbuster product if it ever reaches patients.
How does it make money?
Editas currently generates almost no revenue — it made essentially $0 in product sales because none of its treatments have been approved for sale yet. Like most early-stage biotechs, it survives on collaboration deals and grants, where larger pharma companies pay for access to its technology or research partnerships. It burns through cash — losing around $200 million a year — funding lab work and clinical trials. Until a drug gets approved and sold, this company is entirely dependent on raising money from investors or partners to stay alive.
Why do investors care?
The investment story here is a classic biotech bet: you're paying a low price today for the chance that one of their treatments gets FDA approval and becomes a major commercial product. The cholesterol program EDIT-401 targets a huge market — tens of millions of people in the US alone have high LDL — so even a small market share would mean enormous revenue. For the thesis to work, Editas needs its clinical trials to show the therapy is safe and effective, it needs to not run out of money before that happens, and it needs to get there before competitors do.
Deep Dive
MemberA full investor briefing on Editas Medicine, Inc. — history, leadership, risks, and outlook.